Role of Angiogenesis in Pancreatic Cancer Biology and Therapy

Zheng Zhang,Shunrong Ji,Bo Zhang,Jiang Liu,Yi Qin,Jin Xu,Xianjun Yu
DOI: https://doi.org/10.1016/j.biopha.2018.09.136
IF: 7.419
2018-01-01
Biomedicine & Pharmacotherapy
Abstract:Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, and there is a close parallel between disease mortality and incidence. Malignancy is often diagnosed at an advanced stage due to the lack of early symptoms. For the majority of advanced or metastatic pancreatic cancer patients, therapeutic options are limited. Although several new chemotherapeutic regimens have been developed, the overall response rate remains low. Invasive tumour growth and distant metastasis require angiogenesis, a hallmark of cancer, and angiogenic inhibition is a valuable option for cancer therapy. Some anti-angiogenic drugs have been developed for cancer treatment. This review will focus on the role of angiogenesis and anti-angiogenic treatment strategies as well as combination therapy in pancreatic cancer. Translational information from recent molecular biology and animal studies is also summarized. Finally, the dosing schedule for bevacizumab with other chemotherapeutic protocols for pancreatic cancer treatment is discussed.
What problem does this paper attempt to address?